Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Cancer Res. 2011 Nov 22;72(1):33–44. doi: 10.1158/0008-5472.CAN-11-2333

Fig. 2. Cancer signaling bridges (CSBs) and their roles in cancer study and drug discovery.

Fig. 2

(A) CSBs extend the signaling proteins to cancer proteins. (B) Linked cancer types of CSBs. (C) Known anti-cancer drugs targeted on the proteins for signaling pathways, CSBs, and cancer. (D) Extended proteins by CSBs are more likely to be targeted by anti-cancer drugs than non-extended ones (Signaling proteins: P<10−5, Cancer proteins: P<10−14, Fisher’s exact two-tailed test). (E) The overall effects on protein sets evaluated by E-scores (see Supplementary Methods for details). For known anti-cancer drugs, they have significantly higher effects on cancer protein set than those of signaling pathways and CSB proteins (P<10−20, Mann–Whitney U test).